Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
This study has been completed.
Miltenyi Biotec GmbH
Information provided by (Responsible Party):
Joanne Kurtzberg, MD, Duke University Medical Center
First received: December 27, 2007
Last updated: March 16, 2015
Last verified: March 2015
Subjects will be diagnosed with a hematological malignancy (cancer of the blood), which is unlikely to be cured with conventional non-transplant therapy. The best results of bone marrow transplant are obtained with the donor is a relative that has identical tissue type (HLA-type). These subjects will not have such a donor available but they will have a appropriately matching unrelated umbilical cord blood unit (UCB). However, the cord blood unit does not contain a high enough number of cells and may take longer to engraft (or grow). The purpose of this study is to determine whether the addition of stem cells from a family member to supplement a standard unrelated cord blood transplant is safe and will increase the success of the cord blood transplantation procedure. Subjects enrolled in this study will receive an unrelated cord blood transplant plus a haplo-identical (half-matched), T-cell depleted stem transplant from a related donor. The goal of this study is to determine whether the addition of the related stem cells accelerates bone marrow recovery and improves long-term disease free survival.
Myelodysplastic Syndrome (MDS)
Biological: haplo/cord transplant
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Prospective, Phase I/II Trial Determining the Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Banked Unrelated Umbilical Cord Blood Supplemented With Related, Haplo-Identical T-Cell Depleted Stem Cells in Subjects With High Risk Malignancies
Primary Outcome Measures:
- The Number of Participants Reaching Primary Endpoint of Absolute Neutrophil Count (ANC) of 500/uL (Engraftment). [ Time Frame: By day 100 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- 180 Day Survival [ Time Frame: 180 days ] [ Designated as safety issue: No ]
Number of participants alive at 180 days post transplant
- Non-Relapse Mortality at 180 Days Post Transplant [ Time Frame: 180 days ] [ Designated as safety issue: No ]
- Platelet Engraftment (Untransfused and Platelet Count > 50,000) [ Time Frame: Approximately 1 year ] [ Designated as safety issue: No ]
Participants platelet engrafted.
- Incidence of Primary and Secondary Graft Failure [ Time Frame: 100 days post transplant ] [ Designated as safety issue: No ]
Number of participants experiencing graft failure.
- Number of Participants With Acute or Chronic Graft-versus-host Disease (GVHD) [ Time Frame: two years ] [ Designated as safety issue: No ]
Acute and chronic GVHD
- Rates of Leukemic Relapse [ Time Frame: Up to 2 years post transplant ] [ Designated as safety issue: No ]
Number of participants relapsed
- Number of Participants With Donor Cells at 100 Days Post-transplant [ Time Frame: Post transplant ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2012 (Final data collection date for primary outcome measure)
Biological: haplo/cord transplant
T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
|Ages Eligible for Study:
||up to 55 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patient Selection Criteria: Patients with high risk or refractory malignancies, myelodysplasia (MDS) or severe aplastic anemia amenable to stem cell transplantation therapy but lacking conventional related or unrelated donors will be eligible for this trial.
- Have a consenting related haplo-identical (3/6 or 4/6) stem cell donor;
- Have an available 3, 4, 5, or 6/6 antigen matching unrelated UCB unit that will deliver a cell dose between 2.0-5.0 x 10e7cells/kg.
- Not have a consenting 6/6 or 5/6 antigen matched related bone marrow donor or genetically matched unrelated BM or adult stem cell donor.
- Patients must be <55 years of age at the time of study enrollment.
- Patients must have histologically confirmed diagnosis of a hematologic malignancy, MDS or severe aplastic anemia. Eligible patients include the following:
- Patients with high risk ALL in first complete remission, with high risk being defined by the presence of hypodiploidy, t(4;11; MLL. 11q23) or t(9;22), or patients presenting with extreme hyperleukocytosis (initial WBC >500,000/ml) or failure to achieve a complete remission after standard induction therapy.
- All patients with ALL or ANLL in second or subsequent remission.
- Patients with ALL or ANLL in relapse.
- Patients with MDS.
- Patients with CML in any chronic phase, accelerated phase or blast crisis.
- Patients with severe aplastic anemia refractory to medical therapy.
- Patients must not have active CNS disease at the time of study enrollment.
- Patients must have a good performance status (Lansky 80-100%, Karnofsky 50-100%).
- Patients must have adequate function of other organ systems as measured by:
- Creatinine < 2.0 mg/dl and creatinine clearance > 50 cc/min/m2.
- Hepatic transaminases (ALT/AST) < 4 x normal, bilirubin < 2.0 mg/dl.
- Normal cardiac function by echocardiogram or radionuclide scan, (ejection fraction or shortening fraction > 80% of normal value for age).
- Pulmonary function tests demonstrating FVC and FEV1 of >60% of predicted for age. For adult patients DLCO > 60% of predicted. If patient cannot perform PFTs, clearance by the pediatric or adult pulmonologist will be required.
- Patients must not have uncontrolled infections at the time of cytoreduction.
- Patient, parent, or legal guardian must have given written informed consent according to FDA guidelines.
- Patients may not be pregnant or lactating and must have a current negative pregnancy test.
- Patients must have a minimum life expectancy of at least 3 months.
- Patients must have an available related haplo-identical stem cell donor and an available unrelated cord blood donor delivering between 2 x10e7 cells/kg and 5 x 10e7 cells/kg and matching at a minimum of 3/6 HLA loci.
- Patients must be HIV negative.
- Patients must not be concurrently involved in any other clinical trial that affects engraftment or immune reconstitution (e.g. other hematopoietic growth factors).
- Patients must not have any co-morbid condition which, in the view of the Principal Investigators, renders the patient at too high a risk from treatment complications and regimen related morbidity/mortality.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00673114
|Duke University Medical Center Pediatric Blood and Marrow Transplant
|Durham, North Carolina, United States, 27705 |
Joanne Kurtzberg, MD
Miltenyi Biotec GmbH
||Joanne Kurtzberg, MD
||Duke University Medical Center Pediatric Blood and Marrow Transplant
No publications provided
||Joanne Kurtzberg, MD, Professor of Pediatrics, Duke University Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 27, 2007
|Results First Received:
||May 8, 2013
||March 16, 2015
||United States: Food and Drug Administration
Keywords provided by Duke University:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 30, 2015
Bone Marrow Diseases